Pharmacogenetics and Genomics · 2017 · 47 citations · 19 references
MedicineGeneticsPharmacologyMedical GeneticsPharmacogeneticsPharmacogenomicsDiabetes MellitusSodium-glucose Cotransporter 2 InhibitorsCommon Genetic VariantsGenetic PolymorphismsGenetic Risk VariantsMetabolic PolymorphismsPharmacogenetic StudiesSingle-nucleotide PolymorphismsSodium-glucose Cotransporter 2 InhibitionType 2 Diabetes Susceptibility
OBJECTIVE: Inhibition of the renal sodium-glucose cotransporter 2 (SGLT2) is a novel concept in the therapy of diabetes mellitus. In this study, we first assessed whether common single nucleotide polymorphisms (SNPs) in the SGLT2-encoding gene SLC5A2 affect diabetes-related metabolic traits in subjects at risk for type 2 diabetes and, second, whether these have pharmacogenetic relevance by interfering with the response to empagliflozin treatment in patients with type 2 diabetes. PATIENTS AND METHODS: Samples from a metabolically well-phenotyped cross-sectional study population (total N=2600) at increased risk for type 2 diabetes and pooled pharmacogenetic samples from patients from four phase III trials of empagliflozin (in total: 603 receiving empagliflozin, 305 receiving placebo) were genotyped for five common SNPs (minor allele frequencies ≥5%) present in the SLC5A2 gene locus. RESULTS: In the cross-sectional study, none of the SLC5A2 SNPs significantly influenced metabolic traits such as body fat, insulin sensitivity/resistance, insulin release, HbA1c, plasma glucose, or systolic blood pressure when multiple testing was taken into account (all P≥0.0083). Further, no relevant effect on response to treatment with empagliflozin on HbA1c, fasting glucose, weight, or systolic blood pressure was observed for the SNPs tested in the pharmacogenetic study. CONCLUSION: Common genetic variants in the SLC5A2 gene neither affects diabetes-related metabolic traits nor have a clinically relevant impact on response to treatment with the SGLT2 inhibitor empagliflozin.
19
Michael Roden, Jianping Weng, Jens Eilbracht et al. · The Lancet Diabetes & Endocrinology · 2013 · 446 citations